EE575 Cost-Effectiveness Analysis of Liso-Cel in the Treatment of Patients With Refractory or Relapsed Large B-Cell Lymphoma Within 12 Months (LBCL RR≤12) Eligible for Autologous Hematopoietic Stem Cell Transplant (ASCT) in France
Abstract
Authors
C Thieblemont F Colrat R Sellami M Sivignon S Branchoux A Petel G De Pouvourville